Lymphocyte-activation Gene 3 in Non-small-cell Lung Carcinomas: Correlations with Clinicopathologic Features and Prognostic Significance

Overview

Journal Mod Pathol

Specialty Pathology

Date 2021 Dec 9

PMID 34880448

Citations 5

Authors

Daniel J Shepherd

Elisabeth S Tabb

Keiko Kunitoki

M Lisa Zhang

Marina Kem

Jaimie Barth

David A Qualls

Meghan J Mooradian

Justin F Gainor

Mari Mino-Kenudson

Yin P Hung

Affiliations

Soon will be listed here.

Abstract

Lymphocyte-activation gene 3 (LAG-3) modulates the tumor microenvironment through immunosuppressive effects. Its associations with clinicopathologic parameters and prognostic significance in non-small-cell lung carcinomas remain unclear. We examined LAG-3 expression in 368 resected non-small-cell lung carcinomas (including 218 adenocarcinomas and 150 squamous-cell carcinomas) using tissue microarrays, with normalization to CD8 T-cell count (LAG-3/CD8 index), and correlated LAG-3, CD8, and LAG-3/CD8 index with clinicopathologic features, molecular status, and survival. LAG-3 expression in the immune cells (ranged 0.35-540.1 cells/mm²) was identified in 92% of non-small-cell lung carcinomas. In adenocarcinomas and squamous-cell carcinomas, LAG-3 expression correlated with CD8 T-cell count and PD-L1 expression. In adenocarcinomas, high LAG-3 expression (defined as >median) was additionally associated with smoking history, high T stage, aggressive pathologic features (solid-predominant histologic pattern, lymphovascular invasion, and nodal metastasis), and lack of EGFR mutation. In the entire resected tumor cohort and in adenocarcinomas, high LAG-3 and LAG-3/CD8 index were each associated with worse overall survival. In squamous-cell carcinomas, high CD8 was associated with better overall survival. In an exploratory analysis of pretreatment samples from advanced non-small-cell lung carcinoma patients treated with pembrolizumab, high CD8 was predictive of improved overall and progression-free survival, while high LAG-3, but not high LAG-3/CD8 index, was associated with improved progression-free survival. In conclusion, the clinicopathologic correlations and prognostic impact of LAG-3 in non-small-cell lung carcinoma are histotype-dependent, highlighting differences in the immune microenvironment between adenocarcinomas and squamous-cell carcinomas. The predictive impact of LAG-3 warrants further investigation.

Citing Articles

Characteristics of the immune microenvironment and their clinical significance in lung adenocarcinoma patients with different ALK fusion variants.

Xiao Y, Wang H, Lu J, Pang J, Liu S, Zhou Y Transl Lung Cancer Res. 2025; 13(12):3538-3554.

PMID: 39830736 PMC: 11736598. DOI: 10.21037/tlcr-24-682.

Exploring the molecular landscape of lymphocyte activation gene-3: A literature review.

Nie J, Qin X, Tao X, Huang J Medicine (Baltimore). 2024; 103(39):e39622.

PMID: 39331884 PMC: 11441911. DOI: 10.1097/MD.0000000000039622.

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment.

Passaro A, Al Bakir M, Hamilton E, Diehn M, Andre F, Roy-Chowdhuri S Cell. 2024; 187(7):1617-1635.

PMID: 38552610 PMC: 7616034. DOI: 10.1016/j.cell.2024.02.041.

Landscape of the clinical development of China innovative anti-lung cancer drugs.

Shi Y Cancer Pathog Ther. 2024; 1(1):67-75.

PMID: 38328605 PMC: 10846302. DOI: 10.1016/j.cpt.2022.10.003.

LAG3 in gastric cancer: it's complicated.

Ulase D, Behrens H, Kruger S, Heckl S, Ebert U, Becker T J Cancer Res Clin Oncol. 2023; 149(12):10797-10811.

PMID: 37311986 PMC: 10423140. DOI: 10.1007/s00432-023-04954-1.

References

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Gainor J, Shaw A, Sequist L, Fu X, Azzoli C, Piotrowska Z . EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016; 22(18):4585-93. PMC: 5026567. DOI: 10.1158/1078-0432.CCR-15-3101. View

Zhang M, Kem M, Mooradian M, Eliane J, Huynh T, Iafrate A . Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas. Mod Pathol. 2018; 32(4):511-523. DOI: 10.1038/s41379-018-0160-1. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Al-Shibli K, Donnem T, Al-Saad S, Persson M, Bremnes R, Busund L . Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008; 14(16):5220-7. DOI: 10.1158/1078-0432.CCR-08-0133. View

Bremnes R, Busund L, Kilvaer T, Andersen S, Richardsen E, Paulsen E . The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer. J Thorac Oncol. 2016; 11(6):789-800. DOI: 10.1016/j.jtho.2016.01.015. View

Schalper K, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos K . Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst. 2015; 107(3). PMC: 4565530. DOI: 10.1093/jnci/dju435. View

Lantuejoul S, Sound-Tsao M, Cooper W, Girard N, Hirsch F, Roden A . PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. J Thorac Oncol. 2019; 15(4):499-519. DOI: 10.1016/j.jtho.2019.12.107. View

Dias-Santagata D, Akhavanfard S, David S, Vernovsky K, Kuhlmann G, Boisvert S . Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010; 2(5):146-58. PMC: 3377316. DOI: 10.1002/emmm.201000070. View

10.

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt W . The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11(1):39-51. DOI: 10.1016/j.jtho.2015.09.009. View

11.

Paulsen E, Kilvaer T, Rakaee Khanehkenari M, Al-Saad S, Hald S, Andersen S . Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach. Clin Lung Cancer. 2016; 18(2):220-233.e8. DOI: 10.1016/j.cllc.2016.09.009. View

12.

Triebel F, JITSUKAWA S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E . LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990; 171(5):1393-405. PMC: 2187904. DOI: 10.1084/jem.171.5.1393. View

13.

Demeure C, Wolfers J, Martin-Garcia N, Gaulard P, Triebel F . T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts. Eur J Cancer. 2001; 37(13):1709-18. DOI: 10.1016/s0959-8049(01)00184-8. View

14.

He Y, Yu H, Rozeboom L, Rivard C, Ellison K, Dziadziuszko R . LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. J Thorac Oncol. 2017; 12(5):814-823. DOI: 10.1016/j.jtho.2017.01.019. View

15.

Baixeras E, Huard B, Miossec C, JITSUKAWA S, Martin M, Hercend T . Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med. 1992; 176(2):327-37. PMC: 2119326. DOI: 10.1084/jem.176.2.327. View

16.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

17.

Datar I, Sanmamed M, Wang J, Henick B, Choi J, Badri T . Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. Clin Cancer Res. 2019; 25(15):4663-4673. PMC: 7444693. DOI: 10.1158/1078-0432.CCR-18-4142. View

18.

Andrews L, Marciscano A, Drake C, Vignali D . LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017; 276(1):80-96. PMC: 5338468. DOI: 10.1111/imr.12519. View

19.

Rosenbaum M, Bledsoe J, Morales-Oyarvide V, Huynh T, Mino-Kenudson M . PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol. 2016; 29(9):1104-12. DOI: 10.1038/modpathol.2016.95. View

20.

Li F, Zhang Y, Jin G, Yao L, Wu D . Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. Immunol Lett. 2012; 150(1-2):116-22. DOI: 10.1016/j.imlet.2012.12.004. View